Neurocognitive Outcomes in Mild Hyperphenylalaninemia (MHP)MHP Study

NCT ID: NCT01924026

Last Updated: 2016-02-17

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 10 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2013-09-30
• Study Completion Date: 2016-02-29

Brief Summary

Phenylketonuria (PKU) is a genetic disorder known to cause severe reduction in intelligence and deficits in cognitive function; it is associated with an elevated level of Phenylalanine (Phe) in blood.

Newborn screening and early treatment with restricted protein diet supplemented by a formula of amino-acids will preserve intelligence. In those with the severe form treated from birth, some deficits that affect higher functions of the brain are seen.

Given this, there is disagreement about how milder forms of this disease should be managed and what level of Phe is safe to be left untreated.

We seek to assess whether higher Phe levels, between 360 and 600µmol/L, are safe with respect to preservation of intelligence and higher cognitive functions.

Detailed Description

The following personal/medical information will be collected and reviewed:

• Evaluation of current and past medical history, including psychological treatment such as medication and counseling/therapy.
• Mutational analysis for each MHP subject
• Detailed history of educational, employment, relationship, and socioeconomic status/achievements as a measure of successful transition to adulthood
• Diet history, including past treatment with medical food or Sapropterin (Kuvan) for pre-conceptual and pregnancy Phe management
• All available untreated Phe levels, including newborn screening results (where possible) will be collated to calculate lifetime mean Phe level. Age at collections will be recorded separately for each MHP subjects to ensure inclusion of Phe levels beyond infancy

The following clinical investigations will be administered:

• Measurement of Phe and Tyrosine after an overnight fast, via blood spot using tandem mass spectrometry analysis. Blood spot collection will be done at the same time of day for all subjects.
• Physical exam, height and weight measurements
• Food Frequency Questionnaire assessment to estimate typical daily intake of natural protein.
• Self-Report Questionnaires:

• Behavior Rating Inventory of Executive Function (BRIEF)-A
• Beck Anxiety Inventory
• Beck Depression Inventory
• Quality of Life questionnaire
• Neuropsychological Tests assessed by a trained psychologist

An informant BRIEF-A report will be completed for each subject. To ensure consistency in rating, the same informant will be used where possible for the MHP subject and their sibling control (i.e. parents). These questionnaires will be mailed to the informants and returned to the study site via FedEx.

Conditions

Phenylketonuria; Mild Hyperphenylalaninemia

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

Affected MHP

With Phe between 360 and 600 micromoles/L

No interventions assigned to this group

Unaffected Siblings

With normal Phe levels

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Male or Female, ≥ 18 years
• Confirmed to have MHP with at least two Phe levels during lifetime of above 360µmol/L and below 600µmol/L, including newborn screening levels (available since 1968 by either bacterial inhibition, enzymatic or tandem mass spectrometry methodology) and via mutation analysis. Those with occasional levels above 600µmol/L will not be excluded provided the majority of available levels fall within the 360-600µmol/L range.
• On an unrestricted diet and not taking medical food. Women who were on dietary or Kuvan® treatment for past pre-conception or pregnancy management will not be excluded
• Willing and able to give consent and comply with study procedures.

Exclusion Criteria

• Subjects on dietary or Kuvan® treatment within the last 12 weeks will be excluded.
• Co-morbidities that may interfere with study participation and/or put the subject at a higher risk of adverse effects.

Subjects who do not have an unaffected sibling may still participate.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

BioMarin Pharmaceutical

INDUSTRY

Sponsor Role: collaborator

The Hospital for Sick Children

OTHER

Sponsor Role: lead

Responsible Party

Annette Feigenbaum

Staff Physician, Metabolic Program, Clinical and Metabolic Genetics

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Annette Feigenbaum, MD

Role: PRINCIPAL_INVESTIGATOR

The Hospital for Sick Children

Komudi Siriwardena, MD

Role: PRINCIPAL_INVESTIGATOR

Stollery Children's Hospital

Locations

The Hospital for Sick Children

Toronto, Ontario, Canada

Countries

Canada

Other Identifiers

1000039726

Identifier Type: -

Identifier Source: org_study_id